{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:46:53Z","timestamp":1792108013194,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003715","name":"Korea Research Institute of Bioscience and Biotechnology","doi-asserted-by":"publisher","award":["KGM4572222"],"award-info":[{"award-number":["KGM4572222"]}],"id":[{"id":"10.13039\/501100003715","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SARS-CoV-2 receptor binding domains (RBDs) interact with both the ACE2 receptor and heparan sulfate on the surface of host cells to enhance SARS-CoV-2 infection. We show that suramin, a polysulfated synthetic drug, binds to the ACE2 receptor and heparan sulfate binding sites on the RBDs of wild-type, Delta, and Omicron variants. Specifically, heparan sulfate and suramin had enhanced preferential binding for Omicron RBD, and suramin is most potent against the live SARS-CoV-2 Omicron variant (B.1.1.529) when compared to wild type and Delta (B.1.617.2) variants in vitro. These results suggest that inhibition of live virus infection occurs through dual SARS-CoV-2 targets of S-protein binding and previously reported RNA-dependent RNA polymerase inhibition and offers the possibility for this and other polysulfated molecules to be used as potential therapeutic and prophylactic options against COVID-19.<\/jats:p>","DOI":"10.1038\/s42003-023-04789-z","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T14:02:45Z","timestamp":1680962565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions"],"prefix":"10.1038","volume":"6","author":[{"given":"Paul S.","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5046-483X","authenticated-orcid":false,"given":"Shirley","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanseul","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5466-1993","authenticated-orcid":false,"given":"Seok-Joon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre L.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3726-833X","authenticated-orcid":false,"given":"Maisha","family":"Feroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-3704","authenticated-orcid":false,"given":"Fuming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9795-6513","authenticated-orcid":false,"given":"Jung Joo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-5833","authenticated-orcid":false,"given":"Robert J.","family":"Linhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7802-3702","authenticated-orcid":false,"given":"Jonathan S.","family":"Dordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"key":"4789_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19, 409\u2013424 (2021).","journal-title":"Nat Rev Microbiol"},{"key":"4789_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"4789_CR3","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","volume":"386","author":"Y Goldberg","year":"2022","unstructured":"Goldberg, Y. et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 386, 2201\u20132212 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4789_CR4","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk, M. et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New Engl. J. Med. 385, 1474\u20131484 (2021).","journal-title":"New Engl. J. Med."},{"key":"4789_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.abm8143","volume":"375","author":"Y-J Park","year":"2022","unstructured":"Park, Y.-J. et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science 375, 449\u2013454 (2022).","journal-title":"Science"},{"key":"4789_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1126\/science.abd9909","volume":"370","author":"L Cao","year":"2020","unstructured":"Cao, L. et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 370, 426\u2013431 (2020).","journal-title":"Science"},{"key":"4789_CR7","doi-asserted-by":"publisher","first-page":"eabn1252","DOI":"10.1126\/scitranslmed.abn1252","volume":"14","author":"AC Hunt","year":"2022","unstructured":"Hunt, A. C. et al. Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Sci. Transl. Med. 14, eabn1252 (2022).","journal-title":"Sci. Transl. Med."},{"key":"4789_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41594-021-00570-0","volume":"28","author":"W Yin","year":"2021","unstructured":"Yin, W. et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat. Struct. Mol. Biol. 28, 319\u2013325 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"4789_CR9","doi-asserted-by":"publisher","first-page":"e00900","DOI":"10.1128\/AAC.00900-20","volume":"64","author":"C Salgado-Benvindo","year":"2020","unstructured":"Salgado-Benvindo, C. et al. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle. Antimicrob. Agents Chemother. 64, e00900\u2013e00920 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4789_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41421-020-00192-8","volume":"6","author":"PS Kwon","year":"2020","unstructured":"Kwon, P. S. et al. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov. 6, 4\u20137 (2020).","journal-title":"Cell Discov."},{"key":"4789_CR11","doi-asserted-by":"publisher","first-page":"15870","DOI":"10.1002\/anie.202102717","volume":"60","author":"C Nie","year":"2021","unstructured":"Nie, C. et al. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions*. Angew Chem. Int. Ed. Engl. 60, 15870\u201315878 (2021).","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"4789_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/ph15020258","volume":"15","author":"F Zhang","year":"2022","unstructured":"Zhang, F. et al. Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate. Pharmaceuticals 15, 258 (2022).","journal-title":"Pharmaceuticals"},{"key":"4789_CR13","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.ijbiomac.2020.09.184","volume":"163","author":"W Jin","year":"2020","unstructured":"Jin, W. et al. The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica. Int. J. Biol. Macromol. 163, 1649\u20131658 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"4789_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/md19120685","volume":"19","author":"Y Song","year":"2021","unstructured":"Song, Y. et al. Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from Monostroma nitidum. Mar Drugs 19, 685 (2021).","journal-title":"Mar Drugs"},{"key":"4789_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","volume":"183","author":"TM Clausen","year":"2020","unstructured":"Clausen, T. M. et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell 183, 1043\u20131057.e15 (2020).","journal-title":"Cell"},{"key":"4789_CR16","doi-asserted-by":"publisher","first-page":"104873","DOI":"10.1016\/j.antiviral.2020.104873","volume":"181","author":"SY Kim","year":"2020","unstructured":"Kim, S. Y. et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res. 181, 104873 (2020).","journal-title":"Antiviral Res."},{"key":"4789_CR17","doi-asserted-by":"publisher","first-page":"120167","DOI":"10.1016\/j.carbpol.2022.120167","volume":"299","author":"F Eilts","year":"2023","unstructured":"Eilts, F. et al. The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics. Carbohydr. Polym. 299, 120167 (2023).","journal-title":"Carbohydr. Polym."},{"key":"4789_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","volume":"375","author":"R Brun","year":"2010","unstructured":"Brun, R., Blum, J., Chappuis, F. & Burri, C. Human African trypanosomiasis. Lancet 375, 148\u2013159 (2010).","journal-title":"Lancet"},{"key":"4789_CR19","first-page":"244","volume":"36","author":"H Schulz-Key","year":"1985","unstructured":"Schulz-Key, H., Karam, M. & Prost, A. Suramin in the treatment of onchocerciasis: the efficacy of low doses on the parasite in an area with vector control. Trop. Med. Parasitol. 36, 244\u2013248 (1985).","journal-title":"Trop. Med. Parasitol."},{"key":"4789_CR20","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO model list of essential medicines - 22nd list, 2021. Techn. Doc., WHO\/MHP\/HPS\/EML\/2021.02 (2021).","DOI":"10.1530\/ey.19.13.1"},{"key":"4789_CR21","doi-asserted-by":"publisher","first-page":"e01168","DOI":"10.1128\/AAC.01168-19","volume":"64","author":"N Wiedemar","year":"2020","unstructured":"Wiedemar, N., Hauser, D. A. & M\u00e4ser, P. 100 Years of Suramin. Antimicrob. Agents Chemother. 64, e01168\u201319 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4789_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19808-4","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013 (2020).","journal-title":"Nat. Commun."},{"key":"4789_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"4789_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"R Viana","year":"2022","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679\u2013686 (2022).","journal-title":"Nature"},{"key":"4789_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 182, 1295\u20131310.e20 (2020).","journal-title":"Cell"},{"key":"4789_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-021-00863-2","volume":"7","author":"L Wu","year":"2022","unstructured":"Wu, L. et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. Signal Transduct. Target Ther. 7, 8 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"4789_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"4789_CR28","doi-asserted-by":"publisher","first-page":"e0024922","DOI":"10.1128\/jvi.00249-22","volume":"96","author":"Q Geng","year":"2022","unstructured":"Geng, Q. et al. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1. J. Virol. 96, e0024922 (2022).","journal-title":"J. Virol."},{"key":"4789_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1023\/A:1015666024386","volume":"20","author":"M Kaur","year":"2002","unstructured":"Kaur, M., Reed, E., Sartor, O., Dahut, W. & Figg, W. D. Suramin\u2019s development: what did we learn? Investig. New Drugs 20, 209\u2013219 (2002).","journal-title":"Investig. New Drugs"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04789-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04789-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04789-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T14:06:25Z","timestamp":1680962785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04789-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4789"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-04789-z","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}